Emcure Pharma Ahmedabad oncology facility concludes USFDA inspection with no observations
Pune: Emcure Pharma has announced that the United States Food and Drug Administration (USFDA) has concluded a Pre-Approval Inspection (PAI) at the Company's manufacturing facility (Oncology) located at G.I.D.C., Taluka - Sanand, Ahmedabad – 382110, Gujarat, without issuance of Form 483 (zero observations).
The inspection was conducted from June 30, 2025 to July 08, 2025.
Read also: Emcure Pharma incorporates new wholly-owned subsidiary Emcure Wellness
Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.
Read also: Emcure Pharma to acquire remaining stake in arm Zuventus Healthcare
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.